Fovea Pharmaceuticals

About:

Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.

Website: https://www.fovea-pharma.com

Top Investors: Wellcome Trust, Credit Agricole CIB, Forbion Capital Partners, Sofinnova Partners, Abingworth

Description:

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.